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Rare neurological conditions (RNCs) encompass a variety of diseases that differ in
progression and symptoms but typically include muscle weakness, sensory and balance
impairment and difficulty with coordinating voluntary movement. This can limit overall
physical activity, so interventions to address this are recommended. The aim of this
study was to agree a core outcome measurement set for physical activity interventions
in people living with RNCs. We followed established guidelines to develop core outcome
sets. Broad ranging discussions in a series of stakeholder workshops led to the
consensus that (1) physical well-being; (2) psychological well-being and (3) participation
in day-to-day activities should be evaluated in interventions. Recommendations were
further informed by a scoping review of physical activity interventions for people living
with RNCs. Nearly 200 outcome measures were identified from the review with a
specific focus on activities or functions (e.g, on lower limb function, ability to perform
daily tasks) but limited consideration of participation based outcomes (e.g., social
interaction, work and leisure). Follow on searches identified two instruments that
matched the priority areas: the Oxford Participation and Activities Questionnaire and
the Sources of Self-Efficacy for Physical Activity. We propose these scales as measures
to assess outcomes that are particularly relevant to assess when evaluating physical
activity interventions mong people with RNCs. Validation work across rare neurological
conditions is now required to inform application of this core outcome set in future clinical
trials to facilitate syntheses of results and meta-analyses.
Keywords: physical activity, neuromuscular disease, motor neurone disease, Huntington’s disease, inherited
ataxias, hereditary spastic paraplegia, parkinsonism, outcome measurement instruments
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INTRODUCTION
Rare neurological conditions (RNCs), where cases are ≤40
per 100,000 population (1), collectively incur a significant cost
burden to healthcare, social care services and informal care (2).
Despite variability across conditions, many of these conditions
will share symptoms and signs at the level of body function,
activities and participation (3). As such, common approaches
to improve fitness (e.g., cardiovascular and strength training),
activity (e.g., balance and gait training) and participation levels
(e.g., supported self-management) are often implemented in
clinical practice (4–8).
Physical activity is any bodily movement produced by the
muscles that require us to expend energy and can include
structured exercise, active transportation, household chores, and
activity during work, play and recreation (9). Whilst trials of
physical activity interventions in RNCs highlight the potential
of physical activity interventions to improve fitness and function
(10–13) they are often small studies that fail to influence clinical
practice. There are a variety of factors that limit the impact
of these trials, not least the selection of outcome measures.
Measurement constructs may vary from physiological measures
(e.g., strength and fitness), to functional assessments (e.g.,
walking speed, climbing stairs) or quality of life and well-
being outcomes and do not typically take into account patient
preferences (14). If we are to ensure that research is relevant
and able to influence clinical practice and future research, we
need to ensure the use (and reporting) of standardized, relevant
outcome measures within the field that are applicable to people
living with the conditions (15, 16). Importantly, it should not
be assumed that measurement should be restricted to the agreed
core outcomes but rather that these outcomes should always
be gathered and reported to facilitate evidence synthesis across
relevant trials and studies. Core outcome sets have been agreed
for specific target conditions for example cancer, rheumatology
and chronic pain as well as for specific care pathways for example
maternity care (17, 18).
Core outcome sets have also been proposed for people
with neurologic conditions (19), including adults with dementia
(20). However, these core sets have not been tailored to
physical activity interventions for people living with RNCs.
Recommending measures would not only help to bring
consistency in reporting, allowing comparisons or meta-analysis
of future studies, but also ensure responses are measured of
constructs important to people living with RNCs. This study
focuses on the development of an agreed standardized set of
outcomes termed a “core outcome set” (21) that should be at
a minimum measured and reported in trials of physical activity
interventions in people living with RNCs.
METHOD
The study followed the guidelines of the COSMIN (COnsensus-
based Standards for the selection of health Measurement
INstruments) and COMET (Core Outcome Measures in
Effectiveness Trials) initiatives. A four step approach was used to
select outcome measurement instruments recommended within
core outcome sets (21). The activities relevant to each step within
the process are described in detail below.
We focused on groups of progressive RNCs, namely
neuromuscular diseases, Ataxias, Huntington’s Disease (HD),
Atypical Parkinson Diseases (AP), including Progressive
Supranuclear Palsy, Multiple Systems Atrophy, Corticobasal
Degeneration, Motor Neuron Diseases (MND) and Hereditary
Spastic Paraparesis (HSP). These conditions affect ∼2–10
per 100,000 in the general population, collectively leading to
limited mobility and poor balance for many individuals. People
with neuromuscular diseases and MND experience profound
weakness and muscle atrophy. People with Ataxia, HD, AP,
and HSP experience difficulty controlling movement, with
some muscle weakness and variable cognitive impairment.
Many people across the conditions also experience pain, joint
deformity, fatigue and depression which impacts on their ability
to participate in routine activities of daily living.
Step One: Conceptual Considerations
People living with RNCs, carers of people with RNCs and
representatives from five collaborating support groups and
charities, namely the Muscular Dystrophy Association, Ataxia
UK, HSP support group, PSP Association, HD Association of
England andWales were invited to join a stakeholder group. They
attended an initial workshop (Workshop 1) to define conceptual
considerations in relation to the physical activity interventions
and outcomes in our target population, namely, people living
with RNCs.
This was followed by a second stakeholder workshop
(Workshop 2) with people living with RNC and the relevant
charity representatives. They worked together to (a) explore
issues and experiences relating to physical activity in the face
of living with a RNC and (b) identify and priorities key
constructs and domains of importance that would need to
be measured when evaluating a physical activity intervention.
Representatives from RNC charities were asked to gather views
from their members living with RNCs prior to the meeting
through their communication channels, e.g., surveys and social
media platforms.
Step Two: Finding Existing Outcome
Measurement Instruments
We conducted a scoping review of systematic reviews published
between January 2008 and December 2018 to identify outcome
measures used to measure efficacy of any type of physical activity
intervention for adults with neuromuscular diseases, motor
neurone disease (MND), HD, PSP, multiple system atrophy
(MSA), inherited ataxias and HSP (Open Science Framework
registration: https://osf.io/4cr32/). The research team, experts in
this field, were aware that little research into physical activity had
taken place until the early 2000s and reviews came later, hence
the 10-year window. Studies were included if participants were
adults and if the reviews reported at least one outcomemeasure to
evaluate the efficacy of the physical activity intervention at either
the body structure/function, activity and/or participation levels,
according to the International Classification of Functioning,
Disability and Health (ICF) (20). Constructs and domains of
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importance identified during Workshop 2, were matched with
outcome measures identified in the scoping review. Where no
measures matched the identified, domains, additional literature
searches were done using the domain descriptions as search
terms. Additional criteria for selection were use in RNC or other
neurological diseases. Two of the descriptors, motivation and
confidence, relate strongly to self-efficacy so this was also added
as a search term. Elicitation of stakeholder opinions during a
series of virtual meetings was undertaken to supplement this
process and to identify proposed outcome measures that were
consistent with the domains of importance identified by the
stakeholder group.
Step Three: Quality and Feasibility
Assessment of Outcome Measurement
Instruments
Outcome measurement instruments that are included in a
core outcome set should ideally be reliable and valid for use
in the target populations (22). Feasibility of use is a further
consideration. The rarity of the diseases being studied meant
that the psychometric properties of the measurement tools we
identified had not been examined in these conditions. We thus
considered the psychometric properties of the tools as applied to
more common long term, neurological conditions where there
were indications of some common impairments. The evidence
for each was collated for presentation at step four.
Step Four: Reaching Consensus on the
Proposed Core Outcome Set
The outcome measure instruments under scrutiny matching the
agreed domains of importance were examined by individual
researchers then presented to the wider research team for
technical discussions of the psychometric properties through
a series of video meetings. Following the video meetings, lists
of items assessed within each instrument were sent to the
stakeholder group via e-mail to elicit further reflection on their
relevance to the constructs of importance. A final face to face
stakeholder workshop (workshop 3) and consensus procedure
was undertaken to agree on the instruments for each outcome
to be recommended for inclusion in the core outcome set.
RESULTS
Step One: Conceptual Considerations
People living with RNCs (workshop 1 N = 5; workshop 2 N
= 3), carers (workshop 1 N = 1) and charity representatives
(workshop 1 N = 5; workshop 2 N = 5) considered it
important that measurement tools were able to detect outcomes
across domains of (A) function and well-being and (B)
participation in activities. In terms of (A), staying well, ensuring
good sleep and maintaining positive mood were of highest
priority whilst in relation to (B), the ability and confidence
to take control and make choices along with normalization of
participation and social engagement were important. Through
further discussion, the stakeholder groups agreed that these
aspects were well-centered around (i) physical well-being; (ii)
psychological well-being and (iii) participation in day-to-day
activities as the primary domains of meaningful importance.
Relevant constructs within the physical domain were physical
function and independence. Constructs in the psychological well-
being domain were emotional well-being, mood, enjoyment,
motivation for physical activity and confidence, whilst leisure
activities, work and activity that matters (personal choice) were
constructs of importance within the domain of participation.
Step Two: Finding Existing Outcome
Measurement Instruments
Database searches identified 5,435 articles, and, after removing
duplicates, 4,433 were screened by titles and abstracts, leaving
62 articles for full-text eligibility assessment. They were screened
and 27 were included in the scoping review (4, 5, 8, 12, 13,
23–44). The results of the scoping review will be presented
in detail separately. Nearly 200 outcome measures assessing
outcomes of structured physical activity interventions (Table 1)
were identified within these 27 articles. Dosage, intensity and
duration of training regimes were highly variable but typically
involved strength training, aerobic and respiratory, functional
training and combined programs with very few focusing on
physical activity behavior change.
We mapped each outcome to the World Health Organisation
International Classification of Function (ICF) domains (20)
(see Table 2). The majority were related to function and
activity. Outcomes reflective of both body structure impairments
and participation were less frequently reported. Two domains
were categorized as “Other” (e.g., Goal attainment score),
and “Disease-specific” questionnaires (e.g., Unified Huntington’s
Disease Rating Scale or Scale for the Assessment and Rating
of Ataxia).
Eleven reviews utilized disease-specific outcome measures,
while in six reviews measures were not able to be represented
within the ICF domains (i.e., in the “Other” category). Most
studies (n = 17) included outcomes that were representative of
three to five different domains. Notably, there was no evidence
of stakeholder engagement or involvement of people with the
condition being investigated in the selection of measures used as
primary outcomes.
Constructs relevant to the physical and psychological well-
being, and participation in day-to-day activities domains
were cross-checked with the outcomes synthesized in
the scoping review. No single outcome measurement
instrument that addressed all three domains was identified.
Measures were usually tailored to specific activities or
functions (e.g., on lower limb function, ability to perform
daily tasks). Alternative outcomes reflective of well-
being were reviewed by stakeholders through a series
of group discussions. None of these comprehensively
matched the domains of importance identified in
Step One.
Further literature searching resulted in the Oxford
Participation and Activities Questionnaire (Ox-PAQ)
(50, 51) being identified as an instrument that matched
the majority of the constructs highlighted as relevant in






































TABLE 1 | Characteristics (including outcome measures utilized) reported in studies included in scoping reviews of physical activity interventions in RNCs.




Participant characteristics Controls Outcome measures




Study 1: 52.4 (range: 28–67)
Study 2: 62.5 (range: 39–83)
No controls Performance and satisfaction/Muscle strength/Grip force and pinch
grip (Grippit)/Fine motor control (Purdue Pegboard), Range of
Motion (goniometer). Activities of daily living (interview with
ADL-Taxonomy); Life satisfaction (modified Life Satisfaction Checklist)
Habers and Takken (27) 2 RCTs, 1 non-RCT, 9
uncontrolled studies
161 Male, N = 57; Females, N = 104
Mean Age (Y): range 40–68
Not reported Disease activity (e.g., serum levels of creatine kinase, aldolase,
cytokines etc.)/Muscle strength/Aerobic fitness/Functional
performance/Functional capacity/Health status/Lung function/Muscle
characteristics/Disease impact/Fatigue
Quinlivan et al. (13) 3 non-randomized
studies
27 2 out of 3 studies reported gender: 9
males and 9 females in total. Mean Age
(Y): range 32–61





Borg rating of perceived exertion/VO2 max /HR/Superficial EMG for
muscle activity and glucose and lactate blood levels/Serum creatine
kinase /Respiratory gas exchange/Cardiac output and serum samples
for lactate and glucose were measured/Needle muscle biopsy of
vastus/Respiratory gas exchange data were collected/VO2 peak, and
gross mechanical efficiency during the constant workload test/HR using
12 lead ECG tracing/Capillary blood samples lactate and ammonia
Ydemann et al. (28) 1 Pre-post cohort, 4
RCTs, 1 prospective
cohort, 1 quasi-RCT, 1
descriptive study
757 Not reported Standard medical therapy,
usual care, daily interruption
of sedation only, general
physiotherapy alone
6 MWD/MIP/Isometric quadriceps force/Subjective feeling of functional
well-being/Time in bed/ICU stay/Hospital stay/Duration of
delirium/Ventilator-free days/Muscle fatigue and isotime
dyspnoea/Atrophy/Weaning of atrophy (no further details provided)
Voet et al. (23) 4 RCTs and 1 quasi
randomized study
170 20 adults with mitochondrial myopathy,
diagnosed on the basis of clinical, familial
and muscle biopsy data.
35 adults with myotonic dystrophy type 1,
genetically confirmed.
36 adults with myotonic dystrophy (2
congenital form, 34 classical adult type),
diagnosis not verified.
65 adults with FSHD,
genetically confirmed.
9 adults with dermatomyositis and 5
adults with polymyositis.
Strength training vs. no
training
Differences in Muscle strength (using dynamometer)/Quantitative
Muscle Assessment fixed myometry testing system/Dynamic strength
was evaluated using the one repetition maximum / Weight-lifting
capacity/ Endurance time measured in a submaximal cycling test at a
constant workload of 70%/ 6 MWT, VO2 max/ Maximum duration of
contraction at 80% of MVIC on an isokinetic dynamometer/Sickness
Impact Profile and the Symptom-Checklist /Nottingham Health Profile/
SF-36 Health Survey/ CIS-fatigue
Gianola et al. (25) 4 (3 controlled and 1
randomized clinical)








Maximal voluntary isometric contraction /Maximal peak
torque/Modified MRC/Six-Minute Bicycle Test/BORG/Six-minute walk
test (m)/Timed-stands test/Timed up-and-go test/MVIC isokinetic
torque/Test 80% MVC (sec)/Descending stairs/Climbing
stairs/Standing up from a chair/Standing up from lying supine/Walking




5 Class III studies 62 12 patients with Welander distal myopathy
9 ambulatory patients with LGMD2I and 9
healthy controls 11 men with BMD and 7
healthy men 8 patients with hIBM3
secondary to a defect in the MYH2 gene 6
patients with hIBM3 secondary to a defect
in the MYH2 gene
Sedentary, age-matched
controls
Maximal oxygen uptake/Maximal workload, and other patient-reported
outcomes/Maximum workload/Muscle strength/Change in the

































































































TABLE 1 | Continued




Participant characteristics Controls Outcome measures






422 Not reported Low-intensity home based
program of maintenance
exercises and education for
self-management (30min




Simatos Arsenault et al.
(12)




133 66 females vs. 67 males Mean Age
(Y): 43.8




FSS/Activity monitor/SF-36, FIS/Perceived mental functioning/Physical
fitness (peak work levels, VO2 mL/min,
mL/kg/min)/Ventilation/Isokinetic leg strength (total work
capacity)/General mobility/Confidence in walking/Cardiorespiratory
cycle ergometer test/Isokinetic muscle strength/Functional outcome of
daily physical activity (RAM)/FIS (cognitive, physical, and social)/GBS
disability score/HADS/RHS/QOL
SF-36/MMT/WHOQOL-BREF/DASS-21/PIPP/Physical fitness (duration
of exercise, distance walking, distance cycling, grip
strength)/Pulmonary fitness (PEFR, FVC, FEV1)
Young et al. (29) 1 Randomized
controlled single blind
trial
29 Not reported No strength training Muscle strength voluntary contraction/Isokinetic knee torques/Timed
functional activities




134 Average age: 38 years old.
8 out of 9 studies reported gender: 52%




training was managed by a
physiotherapist instead of a
mechanical apparatus
Muscle strength (N or Kg)/Maximal voluntary isometric testing
(Kg)/Isokinetic knee torque flex/extension/MVC/Endurance test at 80%
MVC/Isokinetic muscle strength (Nm)/Medical research council scale
(MRC)/BOT (balance) score/Power/Long jump (cm)/6 MWT/Walking
ability (different parameters)/Functional activities (e.g., Chair
raise)/CMTES/Phone FITT FDI/ROM/Tinetti Scale/Berg Balance
scale/Physiological (BMI,FFM, Percent body fat, Serum myoglobin,
RMS (µv)/Fatigue Severity Scale/Modified PCI/MHC/Myosin heavy
chain/Cardiorespiratory cycle test/Mean blood CK/VAS/VO2
max/HR/Respiratory Borg Scale/METS/Fatigue Borg Scale
Corrado et al. (30) 4 RCTs and 1 Cohort 236 Not reported No intervention Quantitative neuromuscular assessment/Bioelectrical impedance
analysis/6 MWT/MVC (myometer or isokynetic dynamometre)/Borg
scale/Serum level of myoglobin/Surface electromyography
techniques/Holter
Lui and Byl (33) Prospective clinical
studies (N = 2), RCTs
(N = 2) and 1 SRV
(Dalbello-Haas et al.
(47), previous version of














































































































TABLE 1 | Continued




Participant characteristics Controls Outcome measures
Ng et al. (37) 3 prospective studies,
1 cross-sectional,
pre-post case series
779 Not reported General neurology clinic or
general MND care
Survival, hospital readmissions and length of stay, SF-36, VAS on life
satisfaction and well-being, ALSSS, ALSFRS, CSI, healthcare costs
Dal Bello-Haas and
Florence (4)
2 studies, 6 and 12
month parallel group (1
randomized and 1
quasi randomized trial)
52 27 people with definite or probable,
probable with laboratory-supported MND
(El Escorial criteria), aged 41–80 years.
Early stage MND. 25 people with definite
or probable MND (El Escorial criteria),
aged 41–80 years. Mild to moderate
stages of MND.
The control condition was
either no exercise or
standard rehabilitation
management (for example,
range of motion exercise or
stretching exercise).






and 1 with a historical
control group
87 Male, N = 57; Females, N = 30 Mean Age




Respiratory-related OMs (e.g., Spirom/FVC/MIP/MEP etc.)/Total









Only one study (i.e., single-case study)
reported: one male, age 62 years. Drory
et al. (45) and Bello-Haas et al. (46) and
already presented in previous
systematic reviews.
Training vs no training/or
general care
ALSFR/ Medical Outcomes Survey 36-item/QoL: SF−36/Life
satisfaction and well-being/visual analogue scales ROM/Muscle
strength and shortness/Grip strength/Functional activities—Modified
Norris Limb Scale/Muscle strength measured with Chatillon push–pull
gauge/Survival
Ferreira et al. (35) 3 RCTs 63 Not reported Comparison with controls
who had not received RMT
full time or were receiving
training without load
Ventilatory function FVC, FEV1, MVV/Respiratory muscle strength,
MEP and MIP)/Functional capacity, 6 MWT
Quinn and Busse (38) 4 studies with different
designs: before/after
design (N = 1), single
case (N =1),
observational (N = 1),
RCT (N =1)
63 Male: female = 17:23 (only reported in 1
study - Zinzi et al. (48)). Age not reported
except for one single case study = one




Range of motion/Flexibility/Strength/Co-ordinated and reciprocal
movement/Standing, one foot and kneeling balance/Breathing volume
and control/SF-36/Number of falls/Modified falls scale/Berg Balance
Scale/Self’ paced/Fast paced gait speed/UHDRS/Physical
examinations of posture/Zung depression scale/MMSE/Barthel Index
(ADL)/Tinetti scale (balance)/PPT/Rehabilitation evaluation scale
(REHAB)/BMD/Interact (behavior assessment)/HR/BP/RR/SHRS
Fritz et al. (39) 2 Observational
(without control), 6
RCTs, 7 Pre-Post
control group studies, 2
Pseudo RCT, 1 single
case study
435 Male = 47.25% Mean Age (Y):
range 28–57
Usual care (N = 2), no
progression in resistance
training (N = 1), sham (N =
1), otherwise not specified
Balance/Fitness (cardiovascular function)/Goal attainment/Motor
function and performance/Muscle strength/Number of falls/Physical
activity/Pulmonary function/Rate of chest infections/Ulcer
staging/Spatiotemporal and kinematic parameters of gait and
balance/Walking ability and endurance/Outcome measures of cognitive
function included cognition and psychological measures (depression,
anxiety, and apathy)
Koopman et al. (31) 3 RCTs (2 included in
the scoping review)
120 One study was conducted in elderly
people (no details provided). No details are
reported in the other studies
No treatment or usual care Self perceived activity limitations (e.g., Physical Component Summary
of the SF-36 PCS/Physical mobility category of the Nottingham Health
Profile)/Muscle strength/Muscle endurance fatigue/Pain/Adverse events
subdivided into minor adverse events and serious adverse events
Trujillo-Martín et al. (40) 1 Clinical trial (pre-post
design)
87 Mean age (Y), (SD) = 38.1 (10.9) No controls Neurological examination using the Romberg’s Test and a coordination

































































































TABLE 1 | Continued




Participant characteristics Controls Outcome measures
Fonteyn et al. (41) 14 prospective clinical
trials (4 moderate
quality i.e., comparative
studies - 1 on
cerebellar ataxia).
84 Not reported Controls were patients
receiving treatments later or
not specified
Balance/gait/muscle strength/range of motion/ataxia severity/fall
frequency/gait speed/ADL/FIM/Barthel Incapacitation scores/Hamilton
Rating Scale for Depression/WHOQOL-BREF/NESSCA/SARA
Marquer et al. (43) 19 studies including
MS and traumatic
causes. In this scoping
review only 4 were
included: 1 RCT and 3
observational studies.
However, 3 of these
were already included
in Fonteyn et al. (41).
Only Foltz and Sinaki
(49) is described in the
scoping review.
19 Not reported No controls Subjective self-evaluation of balance
Milne et al. (42) 4 RCTs 1 Pseudo-RCT
4 Interrupted time
series without a parallel
control group 5
Case series
292 in total (21
were not adults) =
271
Mean age range (Y): 23.3–62.5A total of
228 participants (out of 292) were
ambulant, and 72 were non-ambulant. In 2







health education and upper
limb exercises (compared to
a cycling regime) or a
control group receiving
sham vibration over the
same duration (compared to
stochastic vibration)
SARA/FIM/Gait speed/ cadence/ FAC/ Number of falls/ ICARS (8
items)/10 mWT/ Gait speed/ Standing capacity/ Spread of feet/ Body
sway/ Knee to tibia test/ Action tremor/
SF-36/EQ-5D/EQ-VAS/ABC/SCAFI/INAS/GAS/BBS/Kinematic and
kinetic gait parameters/Static balance test/ Dynamic balance
acceleration treadmill task/DGI/ TUG/ FRT/ ABC/ Sway amplitude/
Spatiotemporal/ gait parameters/ FES-I LOS/ SOT/CoP area of 95%
confidence/Ellipse CoP sway path/ CoP mean velocity/ Barthel
WHOQOL-BREF/ MBI/ 5-item Barthel Index/ Obstacle avoidance task
on a treadmill/ EFAP obstacle subtask/ Sway area





Not reported Balance exercises only Kinematic gait measures (stance time, swing time, and step
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Participant characteristics Controls Outcome measures






88 Gender (number of F/M), information only
in 3 studies: Case series 1: 6/2 Case
series 2: 3/7 Case series 3: 2/3
Balance exercises only
[same studies as in (44)]
BBS/ ABC Scale/Sharpened Romberg Test/ FRT/360 turns/ TUG test/
6-MWT/10-WMT/15.2-meter walk test/8-foot (2.4-me) walk
test/5-step test/Balance and gait parameters/ABF device/Static and
dynamic baropodometry/Computerized systems including the
GAITRite system/3D-GA/Force platforms/PSPRS/UPDRS
6 MWT, Six Minute Walking Test; RM, Repetition Maximum; VO2 max, Maximal Oxygen uptake; 6 MWD, Six Minute Walking Distance; ICU, Intensive Care Unit; CIS-fatigue, Checklist Individual Strength; MVC, Maximum Voluntary
Contraction; MVIC, Maximum Voluntary Isokinetic Strength; PIPPS, Perceived Impact of Problem Profile Scale; ESS, Environmental Status Scale; CK, Serum creatine kinase; ALS, Amyotrophic Lateral Sclerosis; ALS-FRS, Amyotrophic
Lateral Sclerosis Functional Rating Scale; EQ-VAS, EQ–Visual Analogue Scale; DGI, Dynamic Gait Index; LGMD1, Limb-girdle muscular dystrophies autosomal dominant; LGMD2, Limb-girdle muscular dystrophies autosomal recessive;
MND, Motor Neurone Disease; RCT, Randomized Controlled Trial; PNF, Proprioceptive Neuromuscular Facilitation; SRV, Systematic Review; ALSFRS, Amyotrophic Lateral Sclerosis Functional Rating Scale; MT, Manual Muscle strength
Testing; FSS, Fatigue Severity Scale; FIM, Functional Independence Measure; FVC, Forced Vital Capacity; BiPAP, Biphasic Positive Airway Pressure; MIP, Maximum Inspiratory Pressure; MEP, Maximal Expiratory Pressure; HRSD,
Hamilton Rating Scale for Depression; ESS, Environmental Status Scale; EQ-5D, Health Status questionnaire; SF-36, Short Form-36 Health Survey; SNIP, Sniff Nasal Inspiratory Pressure; RMT, Respiratory Muscle Training; FEV1, Forced
Expiratory Volume; MVV, Maximum Voluntary Ventilation; QoL, Quality of Life; CMTES, Charcot-Marie-Tooth; Examination Score; FITT, Frequency-Intensity-Time-Type; ROM, Range of motion; BMI, Body mass Index; FFM, Fat Free
Mass; RMS, Root Mean Square; PCI, Physiological Cost Index; MHC, Myosin Heavy Chain; VAS, Visual Analogue Scale; METS, Metabolic Equivalent of Task; UHDRS, Unified Huntington’s Disease Rating Scale; MMSE, Mini Mental
Status Examination; PPT, Physical Performance Test; REHAB, Rehabilitation Evaluation Scale; BMD, Behavior and Mood Disturbance scale; HR, Heart Rate; BP, Blood pressure; RR, Respiratory Rate; SHRS, St Hans rating scale;
ADL, Activity Daily Living; LOSWHOQOL-BREF, World Health Organization Quality of Life questionnaire; NESSCA, Examination Score for Spinocerebellar Ataxia; SARA score, Scale for Assessment and Rating of Ataxia; FAC, Functional
Ambulation Classification; ICARS, International Cooperative Ataxia Rating Scale; ABC, Activities specific Balance Confidence; SCAFI, Spinocerebellar Functional Index; INAS, Inventory of Non-Ataxia Signs; GAS, Goal Attainment Score;
BBS, Berg Balance Scale; TUG, Timed up-and-go test; FES, Falls Self-Efficacy Scale; LOS, Limits of stability; SOT, Sensory Organization Test; WHOQOL-BREF, WHO Quality of Life-BREF; EFAP, Emory Functional Ambulation Profile;
RAM, Rotterdam Activity Monitor; FIS, Fatigue Impact Scale; HADS, Hospital Anxiety and Depression Scale; RHS, Rotterdam Handicap Scale; MMT, Manual muscle testing; DASS-21, Depression, Anxiety; Stress scale (short form); PIPP,
Perceived Impact of Problem Profile; PEFR, Expected Peak Expiratory Flow Rate; FEV1, Forced Vital Capacity in 1 s; HRQoL, Health-related Quality of Life; MBI, Modified Barthel Index; MRS, Modified Rankin Scale; HDS, Hughes Disability
Scale; NHP, Nottingham Health Profile; BI, Barthel Index; HAS, Handicap Assessment Scale; ALSSS, Amyotrophic Lateral Sclerosis Severity Scale; CSI, Caregiver Strain Index; BBS, Berg Balance Scale; ABC, Scale Activities-specific
Balance Confidence; FRT, Functional Reach Test; 10-WMT, Ten-Meter Walk Test; ABF, Audio-biofeedback device; 3D-GA, 3D-Gait Analysis; PSPRS, Progressive Supranuclear Palsy Rating Scale; UPDRS, Unified Parkinson’s Disease
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TABLE 2 | Mapping to World Health Organisation international classification of function ICF) domains.












Cup et al. (24) Myotonic dystrophy and Welander distal
myopathy
✓ ✓ ✓
Gianola et al. (25) Muscular dystrophy ✓ ✓
Narayanaswami et al. (26) Welander distal myopathy, Becker muscular
dystrophy, Limb-girdle muscular dystrophies,
Hereditary inclusion body myopathies
✓ ✓
Habers and Takken (27) Idiopathic inflammatory myopathy
(dermatomyositis, polymyositis, and inclusion
body myositis)
✓ ✓ ✓
Ydemann et al. (28) Critical illness myopathy and polyneuropathy ✓ ✓ ✓ ✓
Young et al. (29) Charcot-Marie-Tooth disease ✓ ✓
Sman et al. (5) Charcot-Marie-Tooth disease ✓ ✓ ✓ ✓
Corrado et al. (30) Charcot-Marie-Tooth disease ✓ ✓ ✓
Quinlivan et al. (13) McArdle disease ✓ ✓
Koopman et al. (31) Postpolio syndrome ✓ ✓ ✓
Simatos Arsenault et al. (12) Guillain-Barré Syndrome ✓ ✓ ✓ ✓
Khan and Amatya (32) Guillain-Barré Syndrome ✓ ✓ ✓
Dal Bello-Haas and Florence (4) Motor-neuron disease ✓ ✓ ✓
Lui and Byl (33) Motor-neuron disease ✓ ✓
Eidenberger and Nowotny (34) Motor-neuron disease ✓ ✓ ✓ ✓
Ferreira et al. (35) Motor-neuron disease ✓ ✓
Arbesman and Sheard (36) Motor-neuron disease ✓ ✓ ✓
Ng et al. (37) Motor-neuron disease ✓ ✓ ✓
Quinn and Busse (38) Huntington’s disease ✓ ✓ ✓ ✓
Fritz et al. (39) Huntington’s disease ✓ ✓ ✓
Trujillo-Martín et al. (40) Spinocerebellar ataxia ✓
Fonteyn et al. (41) Cerebellar Ataxia ✓ ✓ ✓ ✓
Milne et al. (42) Genetic degenerative ataxia ✓ ✓ ✓ ✓ ✓
Marquer et al. (43) Cerebellar Ataxia ✓
Hajjar and Cooper (44) Progressive supranuclear palsy ✓ ✓
Intiso et al. (8) Progressive supranuclear palsy ✓ ✓ ✓ ✓
Step One and has been used in one RNC disease group
and other neurological conditions (50). Three constructs
(i.e., enjoyment, motivation and confidence) are important
predictors of physical activity behavior and not assessed
within any of the Ox-PAQ items but are relate highly to
self-efficacy. The Sources of Self-Efficacy for Physical Activity
(52) was thus identified as an additional secondary outcome
able to reflect these constructs. Other self-efficacy scales
found in the search were specific to particular diseases and
populations but did not include neurological conditions.
It is important to note that these outcomes were not only
reflective of that which is important to stakeholders but
also additionally are able to provide mechanistic insight
for researchers.
Step Three: Quality and Feasibility
Assessment of Proposed Outcome
Measurement Instruments
The OxPAQ questionnaire is a short, 23-item, patient-reported
outcome measure, that has been specifically developed for cross-
disease application and validated in three long term neurological
conditions (MND, Parkinson’s disease, Multiple Sclerosis) (50).
It was developed using patient interviews and expert reviews
and has a manual and online scoring. The Ox-PAQ reports
on three domains, Routine Activities (14 items), Emotional
Well-Being (5 items) and Social Engagement (4 items). Routine
Activities assesses individuals’ capacity to engage in regular
activities that form the basis of daily life. Emotional Well-Being
provides an indication of current mental health status, while
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Social Engagement assesses whether individuals can maintain
relationships, both personal and from a wider community
perspective. Internal reliability is high (Cronbach’s α 0.81–
0.96) and validity was demonstrated against relevant domains
of the MOS SF-36 and the EQ-5D-5L (50). Sources of Self-
Efficacy for Physical Activity is an 18-item questionnaire that
measures six aspects (3 items for each source) of self-efficacy
for physical activity, specifically: mastery experience, vicarious
experience, verbal persuasion by others, self-persuasion, negative
affective states and positive affective states (52). Items were
pooled from prior qualitative studies, scales of feelings induced
by physical activity and sources of self-efficacy more generally.
It was refined in a study of 1,406 German adults through
principal axis analysis with inter-related factors and confirmatory
factor analysis. It is a reliable (Cronbach’s α 0.75–0.93), valid
(convergent and discriminant).It has not been validated in
neurological populations, but the scale was designed to be
generally inclusive allowing it to be applied across conditions
and populations (52). Other self-efficacy scales target specific
conditions and were not generalizable or applicable to people
with RNC.
Step Four: Reaching Consensus on the
Proposed Core Outcome Set
Following broad group communication and discussions and a
final face to face consensus procedure involving small group
discussions, it was agreed that the Ox-PAQ and the Sources of
Self-Efficacy for Physical Activity measure should be assessed
in trials evaluating physical activity interventions across RNCs
given the ways in which they matched the domains and
constructs of importance identified by the stakeholder group.
This was a group decision by people living with RNC, charity
representatives and the research team at the final workshop.
DISCUSSION
Physical activity research trials in RNCs to date have typically
involved targeted exercise intervention and evaluation at the
specific disease level despite these diseases leading to variable
but similar impairments and functional impacts (for example
fatigue, muscle weakness, balance problems, falls and difficulty
walking). Our scoping review highlighted the prevalence of
interventions, mainly focusing on structured exercise and
typically underpinned by standard approaches (53) highlighting
the role of physical activity and exercise as a critical enabler
of participation for all those living with common and rarer
long term neurological diseases (54). Our scoping review of
the literature identified outcome measures appropriate for the
specific body structure, function and activity level changes
targeted by these interventions, but there was a degree of
mismatch between these outcomes and constructs identified as
important to people living with RNCs (e.g., assessments that
capture changes at the level of participation).
We utilized a person-centered approach leading to the
proposal of a meaningful core outcome measurement set for
use when researching physical activity interventions for people
living with RNCs. Our collaborative and participatory design
involved members of the public, including people living with
RNCs, representatives of charities and support groups for RNCs
and is the first core outcome set to our knowledge which has
specifically focused on physical activity interventions for RNCs.
Stakeholder engagement is receiving increasing recognition
in patient-reported outcomes research (18) and clinical trials
(55, 56) so as to ensure that interventions and outcomes are
relevant to the target populations. A core outcome set for
disease modification trials for dementia has been developed with
stakeholder input and involvement of the research community.
This was achieved through a number of stages, including a
systematic review of outcome measures, a consultation with
patient and public involvement representatives and a final
consensus reached with the dementia research community (20).
A similar approach was used to develop a core outcome
measure set for exercise studies in Multiple Sclerosis (57),
where a group consisting of experts in the field, support group
representatives and expert patients, jointly discussed a pre-
defined core set for Multiple Sclerosis. This was based on
the World Health Organisation International Classification of
Function and included body structure and function, activity
and participation categories. Our approach differed somewhat
in that we initially elicited discussion and reflection from
our stakeholder groups on the domains considered important
when engaging in physical activity interventions, but without
presenting any work undertaken in previous studies.
Outcomes identified in the scoping review assessed the effect
of physical activity interventions primarily at the level of body
functions and structures, functional activities. There were fewer
identified outcomes at participation level, in contrast to the
domains prioritized by our stakeholder group, namely physical
and psychological well-being and participation to day-to-day
activities. In the scoping review, measures of quality of life and
health-related well-being were identified, but these did not (in the
views of our stakeholder group) sufficiently capture the breadth
of areas of importance in relation to participation and physical
activity in RNCs. For example, the 36-Item Short Form Survey is
more focused on levels of vigorous andmoderate activities, rather
than independence in day-to-day activities. The Ox-PAQ and
the Sources of Self-Efficacy for Physical Activity measure were
however considered to reflect meaningful outcomes of physical
activity interventions for people with RNCs.
Whilst the identified and proposed outcomes are clearly
relevant to people with RNC, it is not yet clear how well the
measures perform within and between these populations nor
whether they fully capture that which is meaningful to people
with RNCs. For example, the Sources of Self-Efficacy Scale may
not fully capture enjoyment for physical activity; it may be that a
purpose developed enjoyment scale (58, 59) is more appropriate
in different settings. The broad range of rare neurological diseases
where physical activity interventions are indicated are a specific
challenge. A key limitation is that we did not consistently have
stakeholders present at all workshops with faster progressing
conditions, those with significant cognitive disorders or carers,
relying on the charity representatives to bring accounts of these
experiences. People were invited, but the additional complexity
Frontiers in Rehabilitation Sciences | www.frontiersin.org 10 October 2021 | Volume 2 | Article 705474
Ramdharry et al. Physical Activity in Rare Neurological Conditions
of those conditions may have affected engagement in all steps.
Future validation work will need to include these groups to
inform the implementation of the proposed core outcome set.
CONCLUSION
We propose a core outcome set, developed in collaboration
with people living with RNC and their representatives, for use
in studies of physical activity interventions. The two measures
proposed were selected to include domains of importance to
people living with these diseases.
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